Despite the recent appearance of an exciting new arsenal of effective anti-cancer therapeutic agents (e.g. liposomal drugs, gene therapies, radiolabeled antibodies, and toxins), selectively delivering adequate concentrations of these new agents to tumor cells making up primary and metastatic cancers larger than 1 - 2 cm remains a problem. We propose that whoel body hyperthermia (WBH), can be used to increase both the delivery and cytotoxicity of drugs to tumors, while sparing normal tissue. WBH can (i) increase the permeability of tumor microvasculature, (ii) increase drug passage across the tumor cell membrane, (iii) stimulate release of drugs from liposomes, (iv) increase direct cytotoxicity by increasing the interaction of drugs with sub-cellular targets such as DNA (v) inhibit the repair of drug-induced cellular damage, and (vi) destroy tumor microvasculature, thereby limiting tumor growth and metastasis. This proposal focuses on aspects (i), (iii), and (vi).
The specific aims are A) to use WBH to increase liposome delivery to tumor by increasing tumor microvascular permeability; B) to use WBH once liposomes have accumulated in the tumor to stimulate and synchronize release of drug from the liposome; C) to combine liposomal drug with two heat fractions designed to target microvessel permeability and synchronize drug release from the liposomes in a way which balances tumor control, achieved through direct endothelial cytotoxicity and microvessel destruction, with normal tissue toxicity. We propose to achieve this by administering carefully designed combinations of WBH and Doxil (doxorubicin encapsulated in a pegylated, sterically stabilized liposome) to Fischer rats bearing orthotopically inoculated MTLn3 mammary adenocarcinomas which spontaneously metastasize to lymph nodes. WBH will be administered as LL-WBH [long-duration (6h), low-temperature (fever-like) 39.5-40.0 C) WHB) and SH-WBH [short-duration (1 h), high temperature (41.5 C) WBH]. In order to determine the efficacy of these treatments, we will quantify a) primary and metastatic tumor response, b) normal tissue response, c) plasma drug concentration and drug accumulation in tumor and normal tissues as a function of time (pharmacokinetics), d) microvessel permeability as indicated by VPF/VEGF and Flk-1/KDR levels as a function of time, and e) the time course of tumor microvascular density. The ultimate goal is to develop a treatment, which uses multiple heat fractions, together with liposome-encapsulated agents, to target two different aspects of tumor neovasculature to enhance tumor toxicity. The strategy explored in this proposal has direct relevance to the delivery of many of the innovative, new therapeutic agents. Through such a hyperthermia-mediated multi- pronged attack, we hope to significantly increase the survival and quality of life of patients with common cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA043090-15
Application #
6375761
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1986-07-15
Project End
2003-06-30
Budget Start
2001-07-01
Budget End
2003-06-30
Support Year
15
Fiscal Year
2001
Total Cost
$220,067
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77225
Rowe, R Wanda; Strebel, Frederick R; Proett, Jesse M et al. (2010) Fever-range whole body thermotherapy combined with oxaliplatin: a curative regimen in a pre-clinical breast cancer model. Int J Hyperthermia 26:565-76
Rowe, R Wanda; Tomoda, Masaaki; Strebel, Frederick R et al. (2004) The natural progression of microvasculature in primary tumor and lymph node metastases in a breast carcinoma model: relationship between microvessel density, vascular endothelial growth factor expression, and metastatic invasion. Cancer Biol Ther 3:408-14
Sumiyoshi, K; Strebel, F R; Rowe, R W et al. (2003) The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. Int J Hyperthermia 19:103-18
Toyota, N; Strebel, F R; Stephens, L C et al. (1998) Therapeutic efficacy and apoptosis and necrosis kinetics of doxorubicin compared with cisplatin, combined with whole-body hyperthermia in a rat mammary adenocarcinoma. Int J Cancer 76:499-505
Toyota, N; Strebel, F R; Stephens, L C et al. (1998) Effect of altered duration of 41.5 degrees C whole body hyperthermia in combination with cis-diamminedichloroplatinum (II) on tumor and normal tissue apoptosis and tumor response in rats. Oncol Rep 5:1231-6
Toyota, N; Strebel, F R; Stephens, L C et al. (1997) Long-duration, mild whole body hyperthermia with cisplatin: tumour response and kinetics of apoptosis and necrosis in a metastatic rat mammary adenocarcinoma. Int J Hyperthermia 13:497-506
Matsuda, H; Strebel, F R; Kaneko, T et al. (1997) Long duration-mild whole body hyperthermia of up to 12 hours in rats: feasibility, and efficacy on primary tumour and axillary lymph node metastases of a mammary adenocarcinoma: implications for adjuvant therapy. Int J Hyperthermia 13:89-98
Makino, M; Lodato, R F; Stephens, L C et al. (1996) Protective effect of NG-monomethyl-L-arginine against hypotension inducted by combined tumour necrosis factor-alpha and whole body hyperthermia in rats. Int J Hyperthermia 12:617-34
Sakaguchi, Y; Stephens, L C; Makino, M et al. (1995) Apoptosis in tumors and normal tissues induced by whole body hyperthermia in rats. Cancer Res 55:5459-64
Wondergem, J; Strebel, F R; Stephens, L C et al. (1995) Chronic effect of whole-body hyperthermia combined simultaneously with cis-diamminedichloroplatinum (II) on normal tissue in rat. Int J Hyperthermia 11:37-47

Showing the most recent 10 out of 22 publications